ArticleAnnals of hematology2026
FTO-CHRM3 axis regulates multiple myeloma progression: a machine learning-based identification.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFat Mass and Obesity-Associated (FTO) is linked to multiple myeloma (MM) progression, but its action mechanisms are poorly understood.
methodsMachine learning and correlation analysis identified genes with consistent expression patterns as FTO-associated genes. Additionally, the expression levels of FTO and its associated genes in MM tissues were validated through immunohistochemistry. The impact of FTO-associated genes expression on the immune microenvironment of MM was assessed through immune infiltration analysis. Single-cell RNA sequencing (scRNA-seq) elucidated cellular expression patterns.
resultsFTO was found to be significantly upregulated in MM and associated with poor prognosis. Four potential FTO-associated genes (CHRM3, GINS3, RRM2, and SHCBP1) were identified. Correlation and immunohistochemical analyses further focused the FTO-CHRM3 axis. Functional enrichment analysis unveiled that FTO and CHRM3 were involved in "DNA replication" and "cell cycle". The infiltration of M2 macrophages and eosinophils were altered in high FTO/CHRM3 expression groups. ScRNA-seq highlighted the monocyte-specific expression of SLC8A1 in the calcium signaling pathway in MM.
conclusionThe FTO-CHRM3 axis contributes to MM progression via calcium signaling pathway dysregulation, and the exploration of its underlying mechanisms provides insights for targeted MM interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.